三种化疗方案治疗晚期非小细胞肺癌的疗效分析

目的:评价MVP(MMC VDS PDD)、NP(Vinorelbine PDD)、TP(Paclitaxel PDD)三种化疗方案治疗晚期非小细胞肺癌的疗效.方法:114例晚期非小细胞肺癌患者分为3组,MVP组36例,MMC(丝裂霉素)8mg/m2,静脉推注,d1;Vindesine(长春地辛)3mg/m2,静脉点滴,d1,8;PDD(顺铂)80mg/m2,静脉点滴,d3.NP组4l例,Vinorelbine(长春瑞宾)25mg/m2,静脉点滴,d1,8,PDD 80mg/m2,静脉点滴,d3.TP组37例,Paclitaxel(紫杉醇)175mg/m2,静脉点滴,d1,PDD 80mg/m2,静脉点滴,d3.每4周为1周期,至少2周期.结果:MVP、NP及TP的有效率分别为33.2%、34.1%、40.5%;中位生存期分别为8.2个月、7.1个月、9.1个月;1年生存率分别为30.5%、34.1%、37.8%.主要不良反应MVP组为骨髓抑制及恶心、呕吐;NP组为骨髓抑制、恶心、呕吐及静脉炎;TP组为骨髓抑制、恶心、呕吐、肌肉关节疼痛及脱发.结论:MVP、NP及TP化疗方案在治疗晚期非小细胞肺癌的有效率、中位生存期及1年生存率相似,毒性可耐受.

Clinical Analysis of Three Regimens in the Treatment of Advanced Non-small Cell Lung Cancer

Objective: To evaluate the efficacy and toxicity of combination chemotherapy of Mitomycin plus vindesine plus cisplatin, vinorelbine plus cisplatin and paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods: One hundred-fourteen patients with non-small cell lung cancer were enrolled. Thirty-six patients received MVP (mitomycin 6mg/m2, day1, vindesine 3mg/m2, day1, 8 and cisplatin 80mg/m2, day3 every 28 days). Forty-one patients received NP (vinorelbine 25mg/m2, day1, 8 and cisplatin 80mg/m2, day3 every 28 days). Thirty-seven patients received TP (paclitexl 175mg/m2, day1 and cisplatin 80mg/m2, day3 every 28 days). It lasted for two cycles at lest. Results: The objective response rate was 33.2% in the MVP arm, 34.1% in the NP arm and 40.5% in the TP arm. Median survival was 8.2 months, 7.1 months and 9.1 months.1-year survival rate was 30.5%, 34.1%, 37.8% respectively. The main response were myelosuppression, anorexia, nausea/vomiting on the MVP arm, myelosuppression, anorexia, nausea/vomiting, phlebitis on the NP arm and myelosuppression, nausea/vomiting, nephrotoxicity, shed on the TP arm. Conclusion: In the present study, no significant difference was observed in response rate, median survival or 1-year survival rate between the MVP, NP and TP regimens. The side effects were tolerable.